Drugs / Colloidal pectin bismuth
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT06340334 | Mar 2024 → Sep 2025 | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Completed | Met primary |
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT07122024 Comparator | Feb 2024 → Aug 2025 overdue | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT04209933 Comparator | May → Aug 2020 | Helicobacter pylori infectious disease, gastric cancer | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| — | NCT06004401 Comparator | Aug 2023 → Aug 2025 | — | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Colloidal pectin bismuth | “Rabeprazole quadruple therapy for 14 days (R14 group): Rabeprazole sodium 10 mg + Amoxicillin 1 g + Clarithromycin 500 mg + Colloidal pectin bismuth 200 mg, bid, for 14 days.” NCT07122024 ↗3“Group B subjects received oral Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid.” NCT06340334 ↗ |
| Known as | colloidal bismuth pectin | “Participants were randomly assigned in a 1:1 ratio to a 14-day course of either TA dual therapy (tegoprazan 50 mg twice daily and amoxicillin 1000 mg three times daily) or TBQ...” PMID 42457948 ↗ Jul 2026 |
| Route | Oral | “Colloidal pectin bismuth capsules 200 mg,rabeprazole 10 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth” NCT04209933 ↗ |